{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:39:11Z","timestamp":1789706351219,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jtho.2016.10.023","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T01:45:33Z","timestamp":1479433533000},"page":"477-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"12","author":[{"given":"Hiroyuki","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi","family":"Menju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sonobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primo N.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Date","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.10.023_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.10.023_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajim.20246","article-title":"Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model","volume":"49","author":"Murayama","year":"2006","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.jtho.2016.10.023_bib3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jtho.2016.10.023_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11748-014-0389-7","article-title":"Extrapleural pneumonectomy or pleurectomy\/decortication for malignant pleural mesothelioma","volume":"62","author":"Hasegawa","year":"2014","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2016.10.023_bib5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.10.023_bib6","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2016.10.023_bib7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2016.10.023_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","article-title":"MEK in cancer and cancer therapy","volume":"141","author":"Neuzillet","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jtho.2016.10.023_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.10.023_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in\u00a0vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc1391","article-title":"Hyaluronan: from extracellular glue to pericellular cue","volume":"4","author":"Toole","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2016.10.023_bib12","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-09-0479","article-title":"Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities","volume":"15","author":"Toole","year":"2009","journal-title":"Clin Can Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semcancer.2008.03.005","article-title":"Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan","volume":"18","author":"Tammi","year":"2008","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jtho.2016.10.023_bib14","first-page":"388","article-title":"Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts","volume":"53","author":"Asplund","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib15","first-page":"6118","article-title":"Serum-dependent growth patterns of two, newly established human mesothelioma cell lines","volume":"49","author":"Klominek","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1054\/bjoc.2001.1922","article-title":"Hyaluronan production increases the malignant properties of mesothelioma cells","volume":"85","author":"Li","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.10.023_bib17","first-page":"4516","article-title":"Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells","volume":"54","author":"Asplund","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib18","first-page":"196","article-title":"High CD44 expression on human mesotheliomas mediates association with hyaluronan","volume":"1","author":"Penno","year":"1995","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.jtho.2016.10.023_bib19","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.yexcr.2009.03.002","article-title":"4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3","volume":"315","author":"Kultti","year":"2009","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib20","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1365-2133.2010.09699.x","article-title":"4-Methylumbelliferone inhibits tumour cell growth and the activation of stromal hyaluronan synthesis by melanoma cell-derived factors","volume":"162","author":"Edward","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtho.2016.10.023_bib21","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/bjc.2011.459","article-title":"Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in\u00a0vitro and lung metastasis in\u00a0vivo","volume":"105","author":"Arai","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.10.023_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1476-4598-10-30","article-title":"Inhibition of oesophageal squamous cell carcinoma progression by in\u00a0vivo targeting of hyaluronan synthesis","volume":"10","author":"Twarock","year":"2011","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2016.10.023_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ijc.26014","article-title":"Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in\u00a0vitro and metastatic lesions of bone in\u00a0vivo","volume":"130","author":"Urakawa","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.10.023_bib24","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/0008-5472.CAN-09-3185","article-title":"Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells","volume":"70","author":"Lokeshwar","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/glycob\/cwr158","article-title":"Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice","volume":"22","author":"Piccioni","year":"2012","journal-title":"Glycobiology"},{"key":"10.1016\/j.jtho.2016.10.023_bib26","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-12-3801","article-title":"Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production","volume":"73","author":"Hiraga","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/glycob\/cwt074","article-title":"Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy","volume":"23","author":"Lompardia","year":"2013","journal-title":"Glycobiology"},{"key":"10.1016\/j.jtho.2016.10.023_bib28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2016.10.023_bib29","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/2159-8290.CD-14-0477","article-title":"Universes collide: combining immunotherapy with targeted therapy for cancer","volume":"4","author":"Wargo","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2016.10.023_bib30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2016.10.023_bib31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/onc.2010.555","article-title":"AXL regulates mesothelioma proliferation and invasiveness","volume":"30","author":"Ou","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2016.10.023_bib32","first-page":"5242","article-title":"Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma","volume":"62","author":"J\u00e4nne","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib34","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.10.023_bib35","first-page":"6065","article-title":"Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression","volume":"62","author":"Ramos-Nino","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib36","first-page":"3539","article-title":"Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma","volume":"63","author":"Ramos-Nino","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1476-4598-6-81","article-title":"Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas","volume":"6","author":"Ramos-Nino","year":"2007","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2016.10.023_bib38","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cellsig.2009.12.008","article-title":"AP-1\u2014the Jun proteins: oncogenes or tumor suppressors in disguise?","volume":"22","author":"Shaulian","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.jtho.2016.10.023_bib39","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.cellsig.2013.08.014","article-title":"Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence","volume":"25","author":"Shin","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.jtho.2016.10.023_bib40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.molcel.2010.02.020","article-title":"ERK2 but\u00a0not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events","volume":"38","author":"Shin","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.jtho.2016.10.023_bib41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/0008-5472.CAN-11-1831","article-title":"ERK1\/2 regulation of CD44 modulates oral cancer aggressiveness","volume":"72","author":"Judd","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2008.03.007","article-title":"Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression","volume":"18","author":"Bourguignon","year":"2008","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jtho.2016.10.023_bib43","series-title":"Hyaluronan in Cancer Biology","first-page":"89","article-title":"Hyaluronan-mediated CD44 interaction with receptor and non-receptor kinases promotes oncogenic signaling, cytoskeleton activation and tumor progression","author":"Bourguignon","year":"2009"},{"key":"10.1016\/j.jtho.2016.10.023_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: from adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jtho.2016.10.023_bib45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drup.2008.04.002","article-title":"Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance","volume":"11","author":"Toole","year":"2008","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jtho.2016.10.023_bib46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.cellbio.23.090506.123337","article-title":"Hyaluronan in tissue injury and repair","volume":"23","author":"Jiang","year":"2007","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.jtho.2016.10.023_bib47","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD1, PD-L1 and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.10.023_bib48","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1535-7163.MCT-14-0580","article-title":"Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy","volume":"14","author":"Singha","year":"2015","journal-title":"Mol Cancer Ther"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2017.03.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641633458X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641633458X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T11:56:34Z","timestamp":1536234994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641633458X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S155608641633458X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.10.023","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jtho.2017.03.002","asserted-by":"object"}]},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}